Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
| moderate |
LUCENTIS 10 mg/mL, solution for injection provides a moderate improvement in actual benefit (level III) in terms of efficacy in comparison with VISUDYNE in the treatment of visual impairment due to choroidal neovascularisation secondary to pathologic myopia. |
eNq1mNFu2jAUhu95iij3JISuhU6BamPthtRqjBZt2k1lkkMxc+302Aa6p59D6EYnR20Nvozt/D72f/z5yOnZ+p4FS0BJBe+FSdQKA+CZyCm/64WTm4tmNzzrN9IFWZKdYZ2oFSXtMMgYkbIXlr3RFAiX0Y+ry09g/gcM+40gFdMFZOrZOK0oi74QOb8iRTkmSJeC5sE9qLnIe2Gh1aY1SKVCE0V/JfCXLEgGabxt2e1d3L7bbU/jUuwVqloCXhJ+ZxUF7qSZaUTgakAU3Al8rIn3yEmbyjFIoTGDEVHzEYolzSG3TjEjTILTJLNVfg24ZKDKSazi8SK7l07iZEHWY3gY2oP+YHoHaq2arWbSOW63Tk9Oukfdtpu5uLNVdhfMIuLsNum0W0m7EwOPmc6MdVQ6mjMSqAjzZAuVg+eZ5WkehIcX7c+pLBh5jBaycN0qgsR0A5rz728h5Qpu0BCJmT37T59rxuI3Rj3Z8sJTxCWOBkJzVYONi7HrRgwEV7Cud9SNdGq9zUUK8nCyvwW3U36kp4xmrkwz1NEg1WQ8rEfaQWnwkUiYoD8cfKc8Fyt5eMzs2uop+mJDSqtogXly2z7tniTHx86n6KfJoZo75lyjKCA2AHJ0dsuVIZ+JfYli0tIu9ZSUh8vHTakjMsKgpthpOtLFJOJTbeYt1f0do6rDKvr5/MY1P75pwMfrzadVmua9v866odcHz0021gb+9tyujriXMlijHR1zpQr5Po7nRDYlMTsUzfDwXN+5S/1V4F4u7KqAqdjoKfRpdem93h7XI/bSdb5vibr9f1sKW+dQqGEPHyoae2Pm8PzwGP5Xn3oLe/QMG/6m2dSSRFHBfZU4empV3A/8xld+gQYOX2czWvMaUpuXaVy9xPQbaVy+wvQbfwAVHONB
byESQpy1UNu08HvL
Listen
